Khanna et al. (2021) reported that angiotensin-(1-7), a heptapeptide generated by ACE2, could synergize with axitinib in VEGFR-resistant ccRCC, offering a novel angiogenesis-modulating strategy to combat resistance[121]. Here, KDR is linked to nonpapillary renal cell carcinoma.